Mitotane (2,4′-DDD), Antineoplastic Agent

Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions. - Mechanism of Action & Protocol.

Fluphenazine-d₈ MedChemExpress (MCE) Life Science Reagents

Mitotane CancerIndex

PDF] High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.

Exposure to anticancer drugs modulates the expression of ACSL4 and ABCG2 proteins in adrenocortical carcinoma cells - ScienceDirect

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging

Frontiers Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

Mitotane Tablets Cost-Price In India

PDF) Association of mitotane with chylomicrons and serum lipoproteins: Practical implications for treatment of adrenocortical carcinoma

Mitotane - an overview

Pharmacological profile and effects of mitotane in adrenocortical carcinoma - Corso - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library

Anti-Neoplastic agents (Anti-Cancer)

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging

Viability and apoptosis of H295R cells treated with mitotane and/or